» Articles » PMID: 14615659

Patterns and Correlates of Discontinuation of the Initial HAART Regimen in an Urban Outpatient Cohort

Overview
Date 2003 Nov 15
PMID 14615659
Citations 70
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To describe the patterns and correlates of discontinuation of the initial highly active antiretroviral therapy (HAART) regimen in an urban, outpatient cohort of antiretroviral-naive patients.

Design: Retrospective cohort of 345 randomly selected antiretroviral-naive patients who initiated HAART on 6 selected regimens between January 1997 and May 2001 in New Orleans, LA.

Methods: An investigator reviewed medical records to collect information on concurrent medications, symptoms/diagnoses, staging indicators, and reasons for HAART discontinuation. Proportional hazards regression methods were used to identify predictors of discontinuation.

Results: After a median follow-up of 8.1 months, 61% of patients changed or discontinued their initial HAART regimen; 24% did so because of an adverse event. The events most commonly cited as the cause for discontinuation were nausea, vomiting, and diarrhea. A detectable viral load was associated with discontinuation at any time, while reporting nausea/vomiting or dizziness at the previous visit were associated with discontinuation during the first 3 months on HAART. Nausea/vomiting and not having AIDS at the time of HAART initiation were associated with discontinuation due to an adverse event at any time, while a high viral load, and dizziness or anorexia/weight loss at the previous visit were associated with discontinuation due to an adverse event in the first 3 months on HAART.

Conclusions: Gastrointestinal adverse events of HAART are the most frequently cited reason for discontinuation of HAART. An effort should be made to educate patients about these events and to encourage continued adherence. Additionally, appropriate prophylaxes for these events are warranted.

Citing Articles

Neurological impact of HIV/AIDS and substance use alters brain function and structure.

Haorah J, Malaroviyam S, Iyappan H, Samikkannu T Front Med (Lausanne). 2025; 11:1505440.

PMID: 39839621 PMC: 11747747. DOI: 10.3389/fmed.2024.1505440.


Antiretroviral treatment failure and associated factors among people living with HIV on therapy in Homa Bay, Kenya: A retrospective study.

Masaba R, Woelk G, Siamba S, Ndimbii J, Ouma M, Khaoya J PLOS Glob Public Health. 2023; 3(3):e0001007.

PMID: 36962996 PMC: 10021395. DOI: 10.1371/journal.pgph.0001007.


Magnitude and predictors of first-line antiretroviral therapy regimen change among HIV infected adults: A retrospective cross sectional study.

Alema N, Asgedom S, Maru M, Berihun B, Gebrehiwet T, Atey T Ann Med Surg (Lond). 2022; 81:104303.

PMID: 36147157 PMC: 9486446. DOI: 10.1016/j.amsu.2022.104303.


Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis.

Turvey S, Saxinger L, Mason A Viruses. 2022; 14(3).

PMID: 35336923 PMC: 8949089. DOI: 10.3390/v14030516.


Lack of a Clinically Meaningful Drug Interaction Between the HIV-1 Antiretroviral Agents Islatravir, Dolutegravir, and Tenofovir Disoproxil Fumarate.

Jackson Rudd D, Zhang S, Fillgrove K, Fox-Bosetti S, Matthews R, Friedman E Clin Pharmacol Drug Dev. 2021; 10(12):1432-1441.

PMID: 34676683 PMC: 9298070. DOI: 10.1002/cpdd.1026.